Source chain
SEC filings, XBRL financials, federal awards, insider trades, patents, market data, and location-linked context are fused into one company graph.
Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker GRAL · Nasdaq · DE
Source: SEC EDGAR, XBRL financials, federal awards, insider trades, patents, and the Sprytne company graph. Updated 2026-03-12. This page is refreshed with live page data and deterministic offline enrichments.
GRAIL, Inc. is a U.S. business entity operating within the Medical Laboratories sector (SIC 8071). Publicly traded on the Nasdaq under the ticker symbol GRAL, the company is incorporated in Delaware. Based on SEC EDGAR filings, GRAL reported fiscal year 2025 revenue of $147.2M, reflecting a year-over-year growth of 17.2%. Our proprietary Semantic Risk Score of 18 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 8071 classification, GRAIL, Inc. serves as a key benchmark for investors and analysts monitoring Delaware corporate performance.
Why this page is strong for search, retrieval, and mobile reading.
Source chain
SEC filings, XBRL financials, federal awards, insider trades, patents, market data, and location-linked context are fused into one company graph.
Freshness
The page surface always includes the latest 10-K and 10-Q signals, plus freshness widgets for the most recent filing dates.
Retrieval quality
The page is structured for citations, peer comparison, and mobile scanning instead of burying the answer in long-form text alone.
Compact provenance trail for fast scanning, citations, and model retrieval.
Primary records
SEC EDGAR, XBRL filings, and Secretary of State records form the canonical identity layer.
Enrichment layer
Federal awards, patents, insider trades, stock price, and logistics enrich the company graph without inventing fields.
Cross-links
Related companies, industry pages, city, ZIP, street, and money-place context keep the page connected and retrievable.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Services-Medical Laboratories
Industry mapping: Services-Medical Laboratories
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
Numbers parsed from us-gaap XBRL tags in the company's most recent annual report.View source on SEC EDGAR →
GRAIL, Inc. (GRAL)— Key efficiency & solvency metrics · FY2025
Operating Margin
Sector avg: -51.2%
Net Margin
Sector avg: -14.68%
Debt-to-Equity
Sector avg: -2.63
Current Ratio
Sector avg: 4.8
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total RevenueYoY: +17.2% | $147.2M | $1.52B | ▼ Lagging |
| Net IncomeYoY: +79.9% | $-408,351,000 | — | — |
| Operating MarginOperating income as % of revenue | -382% | -51.2% | ▼ Lagging |
| Net MarginNet income as % of revenue | -277.5% | -14.68% | ▼ Lagging |
| Debt-to-EquityTotal liabilities / stockholders equity. Lower = safer. | 0.13 | -2.63 | ▼ Leveraged |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 11.97 | 4.8 | ▲ Outperform |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 26 companies in SIC 8071.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
GRAIL
GRAVITY RECOVERY AND INTERIOR LABORATORY (GRAIL) MISSION THE GRAIL PRINCIPAL INVESTIGATOR (PI) IS RESPONSIBLE FOR THE SUCCESS AND SCIENTIFIC INTEGRITY OF THE GRAIL MISSION. AS SUCH, THE PI SHALL LEAD THE PROJECT, MANAGE PROJECT RESOURCES, AND DIRECT ALL ACTIVITIES OF THE SCIENCE TEAM CARRIED OUT IN SUPPORT OF GRAIL MISSION. THE PI IS ASSISTED BY A DEPUTY PI AT NASA GODDARD SPACE FLIGHT RESEARCH CENTER (GSFC). THE JET PROPULSION LABORATORY (JPL) SHALL SUPPORT THE PI WITH A PROJECT TEAM EXPERIENCED IN MANAGEMENT, SYSTEMS ENGINEERING, MISSION DESIGN, PAYLOAD DEVELOPMENT, SAFETY AND MISSION ASSURANCE, NAVIGATION, AND MISSION OPERATIONS. SALLY RIDE SCIENCE SHALL SUPPORT THE PI WITH THE IMPLEMENTATION OF THE GRAIL EDUCATION AND PUBLIC OUTREACH PROGRAM. IN ADDITION TO THE PI, THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT) PERSONNEL INCLUDE STUDENT AND POST DOC PARTICIPANTS AND ADMINISTRATIVE AND BUSINESS SUPPORT STAFF. THE CONTRACTOR SHALL BE RESPONSIBLE FOR PROJECT PERFORMANCE OVERSIGHT, INCLUDING: 1. SERVE AS THE SPOKESPERSON FOR THE GRAIL MISSION TO NASA AND EXTERNAL ORGANIZATIONS. 2. PROVIDE SCIENCE TEAM LEADERSHIP AND ESTABLISH AND MANAGE NON-GOVERNMENT (I.E., OTHER THAN JPL OR GSFC) SCIENCE TEAM CONTRACTS AND GRANTS. 3. DEVELOP SCIENCE REQUIREMENTS, SUBORDINATE SCIENCE REQUIREMENTS, AND THE SCIENCE DATA MANAGEMENT PLAN. 4. PARTICIPATE IN ALL PROJECT-LEVEL REVIEWS AS DESCRIBED IN THE GRAIL MASTER SCHEDULE, AND SHALL ATTEND OTHER PROJECT TECHNICAL, SCIENCE, MANAGEMENT, AND E/PO REVIEWS AND MEETINGS AS NEEDED. 5. REVIEW AND CONCUR WITH THE JPL PM ON PROJECT AND ENGINEERING DECISIONS THAT AFFECT MISSION SUCCESS AND SCIENCE INTEGRITY. 6. IMPLEMENT AN EDUCATION AND PUBLIC OUTREACH PROGRAM CONSISTENT WITH NASA GOALS AND POLICIES, INCLUDING THE ESTABLISHMENT AND OVERSIGHT OF THE E/PO CONTRACT TO SALLY RIDE SCIENCE. 7. COLLABORATE WITH THE LUNAR GRAVITY RANGING SYSTEM INSTRUMENT TEAM TO COMPLETE OR REFINE PLANS AND DESIGNS FOR THE TWO INSTRUMENTS. 8. PROVIDE INPUTS FOR THE MISSION OPERATIONS SYSTEM AND GROUND DATA SYSTEM (MOS/GDS) AND INSTRUMENT DEVELOPMENT AND OPERATIONS IN SUPPORT OF THE JPL PMSR AND NASA PDR. 9. ESTABLISH AGREEMENTS FOR INTERNATIONAL SCIENCE PARTICIPATION IN COMPLIANCE WITH FEDERAL REGULATIONS. 10. THE CONTRACTOR SHALL PREPARE AND SUBMIT A FINANCIAL MANAGEMENT REPORT (533M) IN ACCORDANCE WITH DRD 1238MA-001 FOR THE MIT CONTRACT AND ALL SUBCONTRACTORS TO NASA. 11. PERFORM OVERSIGHT OF INTEGRATED FINANCIAL REPORTING FOR THE JPL ACTIVITIES. 12. ESTABLISH THE INDEPENDENT GRAIL STANDING REVIEW BOARD (SRB) MEMBERSHIP FOR NASA LIFE CYCLE REVIEWS, BEGINNING WITH THE PDR, AND DEVELOP EVALUATION PLANS FOR THEIR SUPPORT OF MISSION REVIEWS.
IGF::OT::IGF NEW DARPA CONTRACT - LEIDOS INC - SQUAD X PROGRAM (GRAIL) DARPA SOLICITATION NUMBER: DARPA-BAA-15-26
GRAIL MISSION: PAYLOAD PROCESSING TASK ORDER
GRAIL - GRAVITY RECOVERY AND INTERIOR LABORATORY, PHASE A CONCEPT STUDY
IGF::OT::IGF. PURCHASE OF MOTEK GRAIL SYSTEM FOR PTBRC AT VAMC PALO ALTO.
GRAVITY RECOVERY AND INTERIOR LABORATORY (GRAIL) STANDING REVIEW BOARD (SRB) COST ANALYSIS, SCHEDULE ANALYSIS, AND SUPPORT FOR THE PRELIMINARY DESIGN REVIEW/NON-ADVOCATE REVIEW (PDR)/(NAR)
GRAVITY RECOVERY AND INTERIOR LABORATORY (GRAIL) STANDING REVIEW BOARD (SRB) SUPPORT
THE GRAIL AND LADEE MISSIONS DEMONSTRATED THE INHERENT VALUE OF SKIMMING LOW OVER THE LUNAR SURFACE, YET THEY ONLY PROBED BELOW 10 KM VERY BRIEFLY DURING PERIAPSE PASSAGES. ADVANCED SPACE PROPOSES DEVELOPING THE MEANS FOR FLYING SPACECRAFT IN AN ORBIT THAT REMAINS BELOW 10 KM ALTITUDE FOR WEEKS OR MONTHS, OPENING THE DOOR TO BREAKTHROUGH SCIENTIFIC INVESTIGATIONS. THE PROPOSED WORK WILL STUDY AN INNOVATIVE SYSTEM THAT MAY BE USED TO ACHIEVE SUSTAINED LOW-ALTITUDE LUNAR ORBITAL MISSIONS (SLALOM), ENABLED THROUGH AUTONOMOUS ONBOARD GNC CAPABILITIES AND THE USE OF FLASH LIDAR. THE PROPOSED STUDY EXPLORES THE DYNAMICS OF SLALOM, PERFORMS NAVIGATION ANALYSES, EVALUATES MANEUVER PLANNING METHODOLOGIES, AND RESEARCHES HOW UNIQUE INNOVATIONS IN SPACECRAFT AUTONOMY CAN TRANSFER OPERATIONS FROM THE GROUND TO THE SPACECRAFT. SKIMMING THE LUNAR SURFACE AUTONOMOUSLY WITH A SPACECRAFT THAT REMAINS BELOW AN ALTITUDE OF 10 KM IS A CHALLENGING PROPOSITION THAT REQUIRES AN ENTIRELY NEW APPROACH TO SPACECRAFT NAVIGATION, MANEUVER DESIGN AND EXECUTION, AND SPACECRAFT AUTONOMY. SLALOM, WITH THE REQUISITE BREAKTHROUGH IMPROVEMENTS IN GUIDANCE, NAVIGATION, AND CONTROL TECHNOLOGY, ALLOWS NEW SCIENTIFIC INVESTIGATIONS SUCH AS THE DIRECT SENSING AND/OR CAPTURE OF LUNAR PARTICLES NATURALLY LOFTED BY THE COMPLICATED DYNAMICS OF THE LUNAR EXOSPHERE. THE BENEFITS OF THE PROPOSED INNOVATION IN SPACECRAFT AUTONOMY EXTEND NATURALLY TO OTHER AIRLESS BODIES WHERE SUSTAINED LOW-ALTITUDE ORBITS ARE MISSION ENABLING. THESE INCLUDE, AMONG OTHERS, THE SCIENTIFIC AND COMMERCIAL EXPLORATION OF ASTEROIDS AND THE MARTIAN SATELLITES PHOBOS AND DEIMOS. WHILE THESE APPLICATIONS ARE COMPELLING, ADVANCED SPACE IDENTIFIES THE MOON AS AN IDEAL PROVING GROUND FOR THIS TECHNOLOGY FOR MANY REASONS, NOT LEAST OF WHICH IS TO TAKE ADVANTAGE OF THE WEALTH OF GEODETIC REFERENCE DATA GENERATED BY PREVIOUS MISSIONS AND THE DESIRE FOR LOW-ALTITUDE, HIGH VALUE SCIENTIFIC INVESTIGATIONS IDENTIFIED BY THE LUNAR SCIENCE COMMUNITY.
MOTEK GRAIL SYSTEM FOR GAIT ANALYSIS
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 33 peers in Medical Laboratories (SIC 8071)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
Based on NAICS.
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of Statepublic records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not connected with any government agency.Learn more →